Beijing Business Daily (Reporter Yao Qian) On March 24, the latest approval document issued by the State Food and Drug Administration showed that Fuhong Henlius PD-1 monoclonal antibody slulimumab injection was approved for marketing. Unresectable or metastatic high-grade Microsatellite Instability-High (MSI-H) solid tumors that have failed standard therapy.